"we care for children from birth through adolescence, through anything childhood brings. Our pediatricians and pediatric specialists offer exceptional medical knowledge and clinical skills for children in a caring, compassionate environment."

During the past decade, Craig A. Spiegel, MD conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 4 clinical trials were completed, i.e. on average, 80% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Craig A. Spiegel, MD" #1 sponsor was "Janssen Research & Development, LLC" with 2 trials, followed by "Pfizer" with 2 trials sponsored, "Sunovion" with 2 trials sponsored, "Mead Johnson Nutrition" with 1 trials sponsored and "MedImmune LLC" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Craig A. Spiegel, MD" #1 collaborator was "Danone Institute International" with 1 trials as a collaborator and "Nutricia Liverpool" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Craig A. Spiegel, MD" are "Asthma" (2 trials), "Respiratory Syncytial Virus Infections" (2 trials), "Atopic Dermatitis" (1 trials), "COVID-19" (1 trials) and "Cow Milk Allergy" (1 trials). Many other conditions were trialed in "Craig A. Spiegel, MD" in a lesser frequency.

Most popular intervention types in "Craig A. Spiegel, MD" are "Drug" (6 trials), "Other" (3 trials), "Biological" (2 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "placebo" (2 trials), "Biological/Vaccine: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)" (1 trials), "Crisaborole ointment 2%" (1 trials) and "Enfamil LIPIL with iron" (1 trials). Other intervention names were less common.

The vast majority of trials in "Craig A. Spiegel, MD" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Craig A. Spiegel, MD". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Craig A. Spiegel, MD, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Craig A. Spiegel, MD, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".